Company Overview and News

 
Power Root jumps as coverage initiated with Add rating

2018-09-24 thestar.com.my
KUALA LUMPUR: Shares of Power Root Bhd jumped in early trade Monday as coverage was initiated on the company with an “Add” rating by CIMB Equities Research.
7237

 
Power Root up 3.21% after CIMB Research starts coverage

2018-09-24 theedgemarkets
KUALA LUMPUR (Sept 24): Shares in Power Root Bhd rose 3.21% this morning after CIMB IB Research initiated coverage on the stock at RM1.56 with an “Add” rating and target buy of RM2.07 and said the company is one of Malaysia’s largest coffee manufacturers, commanding a 14.5% share of the Malaysian coffee market as at Sep 2017 (source: Nielsen).
7237

 
CIMB Research starts coverage on Power Root, target price RM2.07

2018-09-24 theedgemarkets
KUALA LUMPUR (Sept 24): CIMB IB Research has initiated coverage on Power Root Bhd at RM1.56 with an “Add” rating and target buy of RM2.07 and said the company is one of Malaysia’s largest coffee manufacturers, commanding a 14.5% share of the Malaysian coffee market as at Sep 2017 (source: Nielsen).
7237

 
Eye On Stock: Power Root

2018-09-01 thestar.com.my
POWER Root Bhd (code:7237) saw two consecutive days of share price increases over Wednesday and Thursday to put it on more bullish footing.
7237

 
Power Root taking a breather, says AllianceDBS Research

2018-08-01 theedgemarkets
KUALA LUMPUR (Aug 2): AllianceDBS Research said Power Root Bhd (Pwroot) had on Aug 1 traded within previous day’s range to form an inside day bar before closing near the day’s low at RM1.59 (down 3 sen or 1.85%).
7237

 
KLCI pares loss but seen staying in the red, tracking region

2018-07-31 theedgemarkets
KUALA LUMPUR (July 31): The FBM KLCI pared some of its losses at mid-morning today but looked poised to end the session in the red as regional markets remained weak.
7083 6491 7251 7060 4065 BC94 SMSN BATS 4162 7237 3034 3794 9334 6033 7123 2852 PNADF 3867 6807 PNAGF SMSD

1
Bursa Malaysia ends at intra-day high

2018-07-27 malaymail - 1
KUALA LUMPUR, July 27 — Bursa Malaysia closed at an intra-day high for the fifth consecutive session this week, lifted by last-minute buying in heavyweight stocks led by Petronas Gas and Axiata.
PNADF PBLOF 7237 1295 BSMAF PNAGF 6033 7123 1818

 
Local equity market looks positive over next 12 months, says AmInvestment Research

2018-07-04 theedgemarkets
KUALA LUMPUR (July 4): The outlook for the local equity market looks positive for the next twelve to eighteen months, backed by steady economic growth, according to AmInvestment Bank Research.
5258 PBLOF 5196 7237 1295

 
The Week Ahead: Awaiting Cabinet line-up and new Umno president

2018-07-03 theedgemarkets
THE ringgit, which last week breached the psychological RM4 mark against the US dollar for the first time in five months, is in the spotlight again. At the time of writing last Friday (June 22), the ringgit fetched 4.0022 against the greenback. The ringgit’s fair value should be 3.80, Prime Minister Tun Dr Mahathir Mohamad told Bloomberg in a June 22 interview. “We would like to strengthen our ringgit, but it should be done naturally,” he said.
SARKF MLYNF 8664 6521 7237 1171 5158 8583 0012 4898 3883 5126 7229 SMEBF 5703 MYTEF MLYBY 4197 5202 7164 5222 1155 4588 4863 3158 4723

14
The Week Ahead: Awaiting Cabinet line-up and new Umno president

2018-06-25 theedgemarkets
The ringgit, which last week breached the psychological RM4 mark against the US dollar for the first time in five months, is in the spotlight again. At the time of writing last Friday (June 22), the ringgit fetched 4.0022 against the greenback. The ringgit’s fair value should be 3.80, Prime Minister Tun Dr Mahathir Mohamad told Bloomberg in a June 22 interview. “We would like to strengthen our ringgit, but it should be done naturally,” he said.
SARKF MLYNF 8664 6521 7237 1171 5158 8583 0012 4898 3883 5126 7229 SMEBF 5703 MYTEF MLYBY 4197 5202 7164 5222 1155 4588 4863 3158 4723

 
Short selling of Power Root suspended

2018-05-28 thestar.com.my
7237

5
Trading ideas: MISC, CCM, Masteel, Power Root, Sime Darby

2018-05-28 thestar.com.my
KUALA LUMPUR: JF Apex Research expects MISC Bhd , Chemical Co of Malaysia Bhd (CCM), Malaysia Steel Works (KL) Bhd (Masteel), Power Root Bhd and Sime Darby Bhd to be among the stocks to watch on Monday.
SMEBF 4197 5098 7237

 
AmInvest Research starts coverage of Power Root, FV RM2.20

2018-04-27 thestar.com.my
KUALA LUMPUR: AmInvestment Bank Research has initiated coverage on Power Root with a buy recommendation and a fair value of RM2.20. It said on Friday this was based on 15 times CY19F price-to-earnings (P/E), representing a 57% upside. It is pegged to its historical average P/E. An estimated dividend yield of 6.4%-8.7% is attractive as well. The research house said FY18 appears to be a blip year with externalities impacting earnings compounded by a corporate reshuffle, which has been unfairly perceived, in its opinion.
7237

 
Analyst reports

2018-04-11 thestar.com.my
UOB Kay Hian said Astro is oversold following the 33% share price retracement in the year-to-date basis (versus the FBM KLCI’s 3.6% gain).
4588 7237 5983 5584

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...